CalciMedica, Inc. · NASDAQ:CALC
CalciMedica — Investor Presentation (November 2026)
26 slides from CalciMedica's investor presentation, November 2026
Slide 1: Corporate Presentation
Corporate Presentation November 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding CalciMedica’s business strategy and clinical development plans; the design and potential benefits of CalciMedica’s product candidates; CalciMedica’s ongoing an
Slide 3: CalciMedica: Leaders in CRAC channel inhibition
CalciMedica: Leaders in CRAC channel inhibition Inhibiting CRAC channels to control excessive calcium signaling and protect organ tissues Two selective Auxora (IV) CM5480 (oral) drug candidates Acute hospital treatment Chronic treatment Therapeutic Focus: Pulmonary hypertension CRAC channel Inhibiti
Slide 4: PH-focused pipeline with human proof-of-concept data expected in mid-2027
PH-focused pipeline with human proof-of-concept data expected in mid-2027 Program Purpose Preclinical Phase 1 Phase 2 Phase 3 Anticipated milestones Pulmonary hypertension ▪ Immediate CRAC channel Auxora – IV¹ inhibition POC Ph1b data — PH Proof-of-concept ▪ Expand into mid-2027 hospitalized PH pati
Slide 5: CRAC channels: tightly regulated channels controlling the calcium stores in cells
CRAC channels: tightly regulated channels controlling the calcium stores in cells Calcium (Ca²⁺) Outside cell Orai1 Cell membrane channel IN HEALTHY TISSUES Calcium enters when internal stores run low. Inside cell Feedback signaling STIM1 prevents unnecessary sensor activation and excess calcium ER
Slide 6: Excessive CRAC channel signaling linked to cardiopulmonary disease processes
Excessive CRAC channel signaling linked to cardiopulmonary disease processes Persistent inflammation Disrupted calcium homeostasis Channel upregulation Sustained CRAC activation and Orai1-mediated calcium signaling + + + Persistent Direct tissue Vascular leakage Vascular and cardiac inflammation inj
Slide 7: Auxora has shown consistent reduction and prevention of respiratory failure, cardiac failure and mortality
Auxora has shown consistent reduction and prevention of respiratory failure, cardiac failure and mortality CARDEA: COVID-19 CARPO: Acute KOURAGE: Acute Acute Pancreatitis COVID-19 Pneumonia Pneumonia Pancreatitis Kidney Injury Phase 2a Phase 2a Phase 2 Phase 2b Phase 2 2026 Years 2019 2020 2021 2024
Slide 8: CRAC channel inhibition for pulmonary hypertension (PH)
CRAC channel inhibition for pulmonary hypertension (PH) 8
Slide 9: PH is a large opportunity with unmet need across all patient groups
PH is a large opportunity with unmet need across all patient groups Group 1 Group 2 Group 3 Group 4 Group 5 Pulmonary Chronic Unclear / Arterial Left Heart Lung Disease / Thrombo- Multifactorial Hypertension Disease Hypoxia embolic PH Mechanisms (PAH) ~40K ~500K ~80K ~10–17K Small numbers Est. US Pa
Slide 10: PH is a large opportunity with unmet need across all patient groups
PH is a large opportunity with unmet need across all patient groups Group 1 Group 2 Group 3 Group 4 Group 5 Pulmonary Chronic Unclear / Arterial Left Heart Lung Disease / Thrombo- Multifactorial Hypertension Disease Hypoxia embolic PH Mechanisms (PAH) Often genetic; Often post acute Often idiopathic
Slide 11: Across all PH groups, elevated pulmonary pressure threatens right ventricular function
Across all PH groups, elevated pulmonary pressure threatens right ventricular function Elevated pulmonary Right ventricular (RV) vascular pressure failure Focus of existing therapies Not directly targeted by existing therapies Existing need: High Unmet need: RV failure pressure persists remains the
Slide 12: CRAC channel inhibition directly targets both elevated pulmonary pressure and reduced right ventricular function
CRAC channel inhibition directly targets both elevated pulmonary pressure and reduced right ventricular function Reduce pulmonary Improve RV vascular pressure Function Pulmonary Right Therapeutic Vascular RV vasculature ventricle (RV) approach Vasodilation remodeling protection Vasodilators +++ + In
Slide 13: CRAC channel inhibition improves lung and heart outcomes across complementary preclinical models
CRAC channel inhibition improves lung and heart outcomes across complementary preclinical models Pulmonary vasculature Heart Pulmonary Vascular Ventricular Ventricular Model and compound pressure ↓ remodeling ↓ function ↑ remodeling ↓ MCT rat¹ CM5480 ✓ ✓ ✓ ✓ Sugen/hypoxia rat² Tool compound ✓ ✓ ✓ ✓
Slide 14: CRAC channel expression increased in patients with pulmonary vascular and cardiac disease
CRAC channel expression increased in patients with pulmonary vascular and cardiac disease Pulmonary Vasculature Heart Pulmonary Arteries Pulmonary Veins Right Ventricle Left Ventricle (PAH) (PVOD) (PAH) (Heart Failure) relative expression Orai1 protein CRAC channel overactivation linked to lung and
Slide 15: CM5480 improved function and reduced remodeling in the lungs and heart in the MCT rat PAH model
CM5480 improved function and reduced remodeling in the lungs and heart in the MCT rat PAH model Pulmonary Vasculature Heart Improved Reduced PVR1 Reduced Pulmonary Vascular Remodeling Cardiac Output Reduced Right Ventricular (RV) Remodeling2 PVR Control + vehicle Control + CM5480 MCT + vehicle MCT +
Slide 16: Direct right ventricle (RV) protection differentiates CM5480 from other therapies
Direct right ventricle (RV) protection differentiates CM5480 from other therapies (unpublished data) Pulmonary artery PAB Tadalafil4 banding model (rat) Metric untreated CM54801 Sotatercept2 Imatinib3 (vasodilator) RV systolic function ↓ ↑ /↓ ↓ RV diastolic function ↓ ↑ ↓ RV hypertrophy ↑ ↓ ↓ ↑ Isol
Slide 17: TAC model of left heart stress supports CRAC channel inhibition for Group 2 PH
TAC model of left heart stress supports CRAC channel inhibition for Group 2 (heart failure) PH Transverse Aortic Constriction Model (TAC) Results1 Mice: 5 weeks of left ventricle (LV) pressure overload, then 3 weeks of a tool Orai1 inhibitor or vehicle EJECTION FRACTION END-SYSTOLIC VOLUME 56.9% → 7
Slide 18: PH Development Plan: Auxora PH data and CM5480 IND submission are mid-2027 milestones
PH Development Plan: Auxora PH data and CM5480 IND submission are mid-2027 milestones Anticipated Milestones 2025 2026 2027 2028 2029 1H 2H 2H 1H 2H 1H 2H 1H AUXORA PH Program (IV — established asset, >350-pt safety database) Ph1b Proof-of-Concept n > 12 pts Data Ph2a Hospitalized PH Patients Data C
Slide 19: Auxora for acute pancreatitis
Auxora for acute pancreatitis 19
Slide 20: Acute pancreatitis: substantial unmet need and a potential $2 billion U.S. market
Acute pancreatitis: substantial unmet need and a potential $2 billion U.S. market High unmet need Potential market opportunity ~255K U.S. AP admissions annually¹ ~$1.6–2.0B Potential annual U.S. market 0 approved therapies in U.S. — care is supportive only ~79,000 episodes × $20,000–25,000/course an
Slide 21: CARPO: completed Phase 2b trial in AP with SIRS
CARPO: completed Phase 2b trial in AP with SIRS Dose-ranging study to establish efficacious dose, safety, target patient population and regulatory endpoints High Dose Auxora 2 mg/kg Days 1-3 N = 216 Medium Dose Auxora 1 mg/kg Days 1-3 Daily inpatient In-person Screening visit and assessments • Asses
Slide 22: Auxora prevented new severe respiratory failure
Auxora prevented new severe respiratory failure 100% reduction in new severe 60% reduction in respiratory failure¹ severe organ failure² 9.4% 9.6% 8.5% 8.3% 3.6% 3.8% 0% 0% Placebo Auxora Auxora Auxora Placebo Auxora Auxora Auxora 0.5 mg/kg 1.0 mg/kg 2.0 mg/kg 0.5 mg/kg 1.0 mg/kg 2.0 mg/kg Each p<0.
Slide 23: CARPO suggests a ~20% placebo event rate with LDH enrichment
CARPO suggests a ~20% placebo event rate with LDH enrichment CARPO analysis Independent publication New-onset severe respiratory failure on placebo LDH (lactate dehydrogenase) was the study’s strongest individual predictor of ARDS2 20.0% 111 ICU patients with 8.5% hypertriglyceridemic acute pancreat
Slide 24: FDA-aligned on the planned Phase 2b design expected to inform a potential future registrational study in AP
FDA-aligned on the planned Phase 2b design expected to inform a potential future registrational study in AP FDA-aligned design Following a Type C Meeting First potential registrational endpoints in AP LDH enrichment marker Establishes the first clinical-trial Evaluating elevated LDH to identify pati
Slide 25: Catalysts
-e CalciMedica Catalysts ese CalciMedica 25
Slide 26: Investment highlights and milestones
Investment highlights and milestones CRAC channel inhibition: new frontier in pulmonary hypertension Advancing two drug candidates, Auxora and CM5480, with recent financing ▪ Pulmonary vascular and direct cardiac protection observed in robust preclinical package ▪ Pulmonary and lung benefits observe